What is Reshape?
Founded in 2018, Reshape provides a sophisticated platform that enables biological researchers to automate visual experiments through instant, high-precision data capture. By integrating advanced imaging and analytical tools, the company empowers research labs to transition away from manual, time-intensive processes toward a more streamlined, data-driven methodology. This technological shift is essential for researchers aiming to achieve deeper insights into biological systems while maintaining rigorous standards of accuracy. Headquartered in Denmark, Reshape serves as a bridge between traditional laboratory practices and the future of automated, high-throughput scientific exploration.
How much funding has Reshape raised?
Reshape has raised a total of $28.1M across 2 funding rounds:
Angel/Seed
$8.1M
Series A
$20M
Angel/Seed (2023): $8.1M with participation from FundersClub, Acme Capital, and Y Combinator
Series A (2024): $20M led by Astanor Ventures, Acme, and Y Combinator
Key Investors in Reshape
Astanor Ventures
Astanor Ventures is a specialized VC firm focused on transforming the global agrifood system by backing sustainable and high-impact innovations from soil to gut.
Y Combinator
A premier startup accelerator based in Mountain View, Y Combinator provides essential seed capital and mentorship to high-growth technology ventures.
Acme Capital
Acme Capital is a San Francisco-based firm that invests in breakthrough enabling technologies and disruptive business models across massive global sectors.
What's next for Reshape?
With this major strategic investment, Reshape is well-positioned to scale its operations and expand its footprint within the global research community. The capital will likely be deployed to enhance the company's proprietary software stack, broaden its market reach, and deepen its integration with existing laboratory information management systems. As the demand for precision in biological research continues to rise, Reshape's focus on automating the visual experimental pipeline will be pivotal in maintaining its competitive edge. The company is expected to leverage this financial backing to solidify its role as an indispensable partner for research institutions and commercial biotech firms alike, driving the next generation of scientific breakthroughs.
See full Reshape company page
